Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Barouch, Dan H.; Tomaka, Frank; Wegmann, Frank; Stieh, Daniel J.; Alter, Galit; Robb, Merlin L.; Michael, Nelson L.; Peter, Lauren; Nkolola, Joseph P.; Borducchi, Erica N.; Chandrashekar, Abishek; Jetton, David; Stephenson, Kathryn E.; Li, Wenjun; Korber, Bette T.; Tomaras, Georgia D.; Montefiori, David C.; Gray, Glenda; Frahm, Nicole; McElrath, M. Juliana; Baden, Lindsey R.; Johnson, Jennifer A.; Hütter, Julia; Swann, Edith; Karita, Etienne; Kibuuka, Hannah; Mpendo, Juliet; Garrett, Nigel; Mngadi, Kathy; Chinyenze, Kundai; Priddy, Frances; Lazarus, Erica; Laher, Fatima; Nitayapan, Sorachai; Pitisuttithum, Punnee; Bart, Stephan; Campbell, Thomas; Feldman, Robert; Lucksinger, Gregg; Borremans, C.; Callewaert, Katleen; Roten, Raphaele; Sadoff, Jerald C.; Scheppler, Lorenz; Weijtens, Mo; Boer, Karin Feddes-de; Manen, Daniëlle van; Vreugdenhil, Jessica; Zahn, Roland; Lavreys, Ludo; Nijs, Steven; Tolboom, Jeroen; Hendriks, Jenny; Euler, Zelda; Pau, Maria Grazia; Schuitemaker, Hanneke

doi:10.1016/s0140-6736(18)31364-3

Cited by 293 publications

(344 citation statements)

References 32 publications

Supporting

Mentioning

319

Contrasting

Unclassified

Order By: Relevance

“…Checkpoint inhibition immunotherapy is beneficial for melanoma patients with brain metastases Patients with melanoma that has spread to the brain had an average survival of 12.4 months if they received a checkpoint inhibitory MAb, compared to 5.2 months in control subjects not treated with immunotherapy. 1 The study, which analyzed > 2,700 patient reports in the US National Cancer Database from 2010-5, also reported a 4-year survival of 28% compared to 11% in the control group.…”

Section: Human Vaccines and Immunotherapeutics: Newsmentioning

confidence: 96%

“…A mosaic HIV vaccine (J&J) elicited immune responses that lasted one year in all participants enrolled in a Phase 1/2 Approach study. 1 The vaccine, which is a composite targeting HIV strains from around the world, is administered in four doses every 12 weeks. A Phase 2 efficacy trial is underway in five southern African countries, involving 2,600 women aged 18-35 years.…”

Section: Experimental Hiv Vaccine Is Immunogenic For At Least One Yearmentioning

confidence: 99%

“…Overexpression of the immune master regulator IKZF1 increased the efficacy of PD-1-and CTLA-4-targeting immunotherapy in a preclinical study. 1 The induced gene, which is associated with cytotoxicity in autoimmune disorders, inhibited cancer growth in mouse models and increased immune susceptibility of tumor-derived cell lines.…”

Section: Induction Of the Transcription Factor Ikzf1 Might Enhance Chmentioning

confidence: 99%

See 2 more Smart Citations

Human Vaccines & Immunotherapeutics: News

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Human Vaccines and Immunotherapeutics: Newsmentioning

confidence: 96%

Section: Experimental Hiv Vaccine Is Immunogenic For At Least One Yearmentioning

confidence: 99%

Section: Induction Of the Transcription Factor Ikzf1 Might Enhance Chmentioning

confidence: 99%

See 1 more Smart Citation

Human Vaccines & Immunotherapeutics: News

2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Cette souche comporte six délétions totalisant 24,7 Ko ainsi que des mutations moins dramatiques affectant 124 cadres de lecture ouverts résultants de 571 passages en culture sur des cellules CEF. Les résultats actuellement les plus prometteurs semblent être son utilisation comme vaccin anti Ebola [22] et anti VIH [23]. À la fin des années 1970, plus de 120 000 personnes avaient reçu ce vaccin sans qu'aucun effet indésirable important n'ait été rapporté [21].…”

Section: Difficultés Rencontréesunclassified

Les vaccins de demain

Lelièvre

2019

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

La vaccination représente une des avancées majeures dans le domaine de la santé. Les premiers vaccins ont été produits sur un concept assez empirique reposant sur la stratégie des « 3 i » : isolement, inactivation, injection. Plus récemment sont apparus les vaccins protéiques. Cependant l'émergence de nouveaux pathogènes, l'inefficacité des stratégies vaccinales actuelles pour protéger contre certaines infections, la nécessité de pouvoir développer rapidement et à bas coût de revient des vaccins ont conduit à développer de nouveaux types de vaccins. C'est dans ce contexte que se sont développés des vaccins basés sur l'utilisation des séquences codantes d'acides nucléiques des antigènes d'intérêt (vecteurs viraux, vaccins ADN, vaccins ARN) visant à améliorer l'efficacité des vaccins actuellement disponibles et à proposer des plateformes génériques potentiellement utilisables contre un grand nombre de pathogènes différents. Outre l'utilisation de ces nouveaux vaccins, les recherches vaccinales en cours bénéficient d'évolutions technologiques visant à délivrer de manière optimale les vaccins, en ciblant par exemple les cellules dendritiques, et de mieux caractériser les antigènes d'intérêt via notamment l'utilisation de la vaccinologie inverse. ABSTRACT Vaccine of the futureVaccination represents one of the major advances in the field of health. The first vaccines were produced on a rather empirical concept based on the so-called 3I strategy: isolation, inactivation, injection. More recently, protein vaccines have emerged. However, the emergence of new pathogens, the inefficiency of these vaccine strategies to protect against several infections, the need to be able to develop new vaccines quickly and at low cost have led to the development of new types of vaccines. In this context vaccines based on the use of the nucleic acid coding sequences of the antigens of interest (viral vectors, DNA vaccines, RNA vaccines) have been developed in order to improve the efficiency of the currently available vaccines and to propose generic platforms potentially usable against a large number of different pathogens. In addition to the use of these new vaccines, ongoing vaccine research is benefiting from technological developments aimed at optimally delivering vaccines, targeting, for example, dendritic cells, and better characterizing the antigens of interest through the use of vaccines of reverse vaccinology. MOTS CLÉS◗ pathogènes émergents ◗ vaccin ADN ◗ vaccin ARN ◗ vaccinologie inverse ◗ vecteurs viraux KEY WORDS ◗ DNA vaccine ◗ emerging infectious diseases ◗ reverse vaccinology ◗ RNA vaccine ◗ viral vectors

show abstract

“…This trial (HVTN 705) is being conducted in young women in South Africa, Zambia, and Zimbabwe, a sub‐Saharan population at particularly high risk for HIV infection. The regimen being used has shown good protection in macaques against serial rectal challenges with a pathogenic clade B simian‐human immunodeficiency virus . This protection correlated with pnnAb.…”

Section: Vaccines and Amp In Ongoing Efficacy Trialsmentioning

confidence: 99%

HIV/AIDS Vaccines: 2018

Robinson

2018

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007. This review, HIV AIDS Vaccines: 2018, focuses on the progress in the past 11 years. I begin with key challenges for the development of an AIDS vaccine and the lessons learned from the six completed efficacy trials, only one of which has met with some success.

show abstract

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Abstract: Janssen Vaccines & Prevention BV, National Institutes of Health, Ragon Institute of MGH, MIT and Harvard, Henry M Jackson Foundation for the Advancement of Military Medicine, US Department of Defense, and International AIDS Vaccine Initiative.

Cited by 293 publications

References 32 publications

Human Vaccines & Immunotherapeutics: News

Human Vaccines & Immunotherapeutics: News

Les vaccins de demain

HIV/AIDS Vaccines: 2018

Contact Info

Product

Resources

About